{"content":[{"text":"Ilypsa and Astellas Enter a Licensing Agreement on ILY101 for Treatment of \n Hyperphosphatemia in Japan","bbox":{"left":0.14183,"top":0.19485,"width":0.716514,"height":0.040105}},{"text":"SANTA CLARA, CA and TOKYO, JAPAN- April 27, 2006- Ilypsa, Inc. (“Ilypsa”; \n headquarters: Santa Clara, California; President and CEO: Jay P. Shepard) and Astellas \n Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Toichi Takenaka) \n announced today that they have entered into a license agreement that gives Astellas \n exclusive rights to develop and market ILY101 in Japan, a drug to treat hyperphosphatemia \n which was discovered by and is under development by Ilypsa.","bbox":{"left":0.128625,"top":0.257843,"width":0.742999,"height":0.12426100000000001}},{"text":"Hyperphosphatemia is associated with abnormally high blood concentrations of phosphorus. \n Normally, phosphorus in the body is excreted into urine via the kidneys, but this process is \n impaired when renal function is reduced. Hyperphosphatemia occurs in many patients \n with renal insufficiency, especially those on dialysis. High blood phosphorus \n concentration triggers various complications caused by phosphorous interaction with blood \n calcium or parathyroid hormones, and makes patients more prone to calcium deposition in \n soft tissues such as the coronary arteries, increasing the risk of ischemic heart disease.","bbox":{"left":0.128826,"top":0.405206,"width":0.747684,"height":0.14549700000000004}},{"text":"ILY101 is a non-absorbed, metal-free polymer that binds phosphorus in the gastrointestinal \n tract, allowing for excretion of phosphorus. It is therefore anticipated to ameliorate \n hyperphosphatemia by reducing the absorption of phosphorus from the gastrointestinal \n tract.","bbox":{"left":0.128826,"top":0.573876,"width":0.742777,"height":0.08221899999999993}},{"text":"“We are delighted to enter into partnership with Ilypsa on ILY101,” said Toichi Takenaka, \n Ph.D., President and CEO of Astellas. “ILY101, with its unique profile, is an important \n addition to our product portfolio in the ethical pharmaceutical business in Japan. I believe \n ILY101 will contribute to physicians and patients by offering a new option for the treatment \n of hyperphosphatemia.”","bbox":{"left":0.128625,"top":0.679268,"width":0.743237,"height":0.10331100000000004}},{"text":"“We are excited to have attracted a leading partner such as Astellas for the development and \n commercialization of ILY101 in Japan. Astellas has the proven pharmaceutical experience \n to enable an accelerated path for bringing this innovative compound to patients in Japan \n where there is significant medical need,” said Jay P. Shepard, President and CEO, Ilypsa, \n Inc.","bbox":{"left":0.128625,"top":0.805752,"width":0.743089,"height":0.10331199999999996}},{"text":"1","bbox":{"left":0.495144,"top":0.950431,"width":0.009807999999999983,"height":0.016634999999999955}}],"images_bbox":[{"left":0.128625,"top":0.072541,"width":0.28889,"height":0.052803},{"left":0.612479,"top":0.067339,"width":0.265011,"height":0.054299}],"images_bbox_not_text_overlap":[{"left":0.128625,"top":0.072541,"width":0.28889,"height":0.052803},{"left":0.612479,"top":0.067339,"width":0.265011,"height":0.054299}]}